DermBiont rais­es $35.2M Se­ries B to ad­vance two der­ma­to­log­i­cal drugs through PhII

Boston biotech DermBiont closed a $35.2 mil­lion fund­ing round Tues­day to ad­vance de­vel­op­ment of two of its der­ma­to­log­i­cal top­i­cal can­di­dates.

The fi­nanc­ing in­clud­ed a $27.1 mil­lion Se­ries B and $8.1 mil­lion in con­vert­ing out­stand­ing notes led by Dou­ble Point Ven­tures to take two of its can­di­dates through Phase II meet­ings with the FDA, ex­pect­ed in the sec­ond half of 2024.

DermBiont piv­ot­ed to small mol­e­cule top­i­cals last year af­ter in­vestors showed lit­tle in­ter­est in mi­cro­bio­me-based ther­a­pies and the com­pa­ny cut its orig­i­nal lead der­ma­tol­ogy gel while end­ing sev­er­al oth­er pro­grams.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER